Floatz logo

nt-0796

Obesity

NodThera LimitedPhase 2Active
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
59/ 100

Competitive context

574 Active assets in the Obesity cohort.

Asset / SponsorPhaseRating
vi-0521
VIVUS LLC
Phase 4BBB
Efsubaglutide Alfa
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 4BBB
Deoxycholic Acid
University of California, San Diego
Phase 4BBB
asc30
Ascletis Pharma (China) Co., Limited
Phase 2BBB
Tirzepatide
LABORATORIOS INDUFAR
Phase 4BBB

View all 50 →

Same molecule, other indications

nt-0796 is also rated in:

Obesity and Type 2 DiabetesDormant
B
Indicative ·
57 / 100
View asset →
cardiovascular disorderDormant
CC
Indicative ·
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →